



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/674,090	03/01/2001	Yoav Eichen	RCP-PT009	1528
3624 7590 08/15/2008 VOLPE AND KOENIG, P.C. UNITED PLAZA, SUITE 1600 30 SOUTH 17TH STREET PHILADELPHIA, PA 19103			EXAMINER PANDE, SUCHIRA	
			ART UNIT 1637	PAPER NUMBER
			MAIL DATE 08/15/2008	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

09/674,090

Applicant(s)

EICHEN ET AL.

Examiner

SUCHIRA PANDE

Art Unit

1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 22 January 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1, 4-9, 18-20, 22-29, 35-39, 41, 43-45, 47-51, 53-57, 60-63 and 65 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 4-9, 18-20, 22-29, 35-39, 41, 43-45, 47-51, 53-57, 60-63, and 65 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

1. This case has been transferred to Examiner Suchira Pande due to Examiner Kim's leave.
2. This office action is in response to an amendment filed on January 22, 2008. Applicant has amended claims 1, 37 and 65; cancelled claims 2-3, 10-17, 21, 30-34, 40, 42, 46, 52, 58-59, 64, and 66; consequently claims 1, 4-9, 18-20, 22-29, 35-39, 41, 43-45, 47-51, 53-57, 60-63, and 65 are currently pending and will be examined in this action.

Response to Arguments

Re 112 second rejections of claims 3, 55, 56, 58 and 59

3. Cancellation of claims 3, 58 and 59 obviates that 112 second rejection of these claims.
4. Applicant has amended base claim 37 by replacing the term microelectronics by means. This amendment to claim language obviates the 112 2nd rejections of claims 55 and 56 raised in last office action by providing the proper antecedent basis. Accordingly the 112 2nd rejections of claims 55 and 56 raised in last office action are moot.

Re 112 1st paragraph enablement rejections of claims 1, 3-9, 18-20, 22-29, 35-36, 38-39, 41, 43-45, 47-51, 53 and 55-61

5. Applicant's arguments on pages 17-21, filed January 22, 2008, with respect to 112 1st paragraph enablement rejections, have been fully considered and are persuasive. Accordingly, the 112 1st paragraph enablement rejection of

Art Unit: 1637

claims 1, 3-9, 18-20, 22-29, 35-36, 38-39, 41, 43-45, 47-51, 53 and 55-61 raised in the office action dated September 19, 2007 has been withdrawn.

Re 112 1st paragraph written description rejections of claims 1, 3-9, 18-20, 22-29, 35-36, 38-39, 41, 43-45, 47-51, 53 and 55-61

6. Applicant's arguments on pages 21-23, filed January 22, 2008, with respect to 112 1st paragraph written description rejections, have been fully considered and are persuasive. The 112 1st paragraph written description rejection of claims 1, 3-9, 18-20, 22-29, 35-36, 38-39, 41, 43-45, 47-51, 53 and 55-61 raised in the office action dated September 19, 2007 has been withdrawn.

Claim interpretation

7. Claims 1, 35, and 37 in the current claim set all recite the phrase "means for". Examiner is interpreting that by using this "means for" language in the claims Applicant intends to invoke 112 6th paragraph. Upon scanning the specification as filed, Examiner has concluded that no explicit support is provided by the specification as filed for term "means for". The application only provides implicit support for "means for" and furthermore Examiner would like to indicate that implicit support for "means for" is also limited to "microelectronics". No other means are implicitly supported by the application as filed.

Continuing the 112 6th par. analysis further, Examiner notes that claims 55, 56, 60-63 provide too much structure, therefore 112 6th paragraph can not be applied to these dependent claims. Examiner did not find support for the limitations recited in claims that were added during prosecution namely computer, and scanner in the application as originally filed. Hence, these claims

Art Unit: 1637

55, 56, 60-63 are being rejected under 112 1st new matter written description rejection.

8. Claim 65 is also being rejected under 112 1st new matter written description rejection because there is no support for the newly added term computer in the specification as originally filed.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

9. Claims 55, 56, 60-63 and 65 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

10. As discussed above, 112 6th paragraph is not being applied to claims 55, 56, and 60-63. Examiner did not find support for the limitations recited in claims that were added during prosecution namely computer, and scanner. Hence, these claims are being rejected under 112 1st new matter written description rejection.

11. Claim 65 is also being rejected under 112 1st new matter written description rejection because there is no support for the newly added term computer in the specification as originally filed.

Claim Rejections - 35 USC § 102

12. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

13. Examiner is considering the claims directed to a system (claim 1); claims directed to a method for assaying (claims 24-26); together in claim 1 as both the system and method claimed contain common elements recited in claim 1. Furthermore they are directed to same invention namely assaying one or more targets in a sample and all the claims share the limitations listed in claim 1. Additional limitations are addressed under the specific claims no.

14. Claims 1, 4-9, 18-20, 22-28, 45 and 57 are rejected under 35 U.S.C. 102(b) as being anticipated by Mroczkowski et al. (WO 90/05300; cited in the IDS).

Regarding claims 1 and 24-26 Mroczkowski et al. teach a system, a method, an assay device for assaying one or more targets in a sample comprising:

(a) an assay device having one or more assay sets (see page 18 lines 1-8 where multiple assay sets are taught), the assay sets comprising at least two electrodes, a substrate, and a recognition moiety; the electrodes positioned on the substrate and separated by a gap (Fig. 1, 2, 4, 6, 7, 8; page 6, lines 14-22; page 11, lines 5-35; page 12, lines 1-33; page 13, lines 6-27; page 14, lines 14-

Art Unit: 1637

22; page 21; page 22, lines 1-27); the recognition moiety positioned in the gap and bound to the substrate (Fig. 1, 2, 4, 6, 7; page 5, lines 21-35; page 6, lines 23-33; page 9, lines 5-14; page 10, lines 7-23);,

the recognition moiety (see page 5 line 29 where antibodies= recognition moiety are taught) being capable of specific binding to a component of a target selected from the group consisting of a bacterium, a virus, and a cell (see page 5 line 6-10 where detection of antigens in the fluids or tissues of human or animals is taught. By teaching antigens Mroczkowski et al. teach a bacterium, a virus, and a cell which all have antigens on their surfaces);

(b) an electric or electronic module arranged and configured to measure electric conductance between the at least two electrodes of each assay set (see page 8 lines 8-14);

(c) reagents formulated to deposit a conductive substance onto a complex formed between said recognition moiety and said target, wherein the reagents comprise: (i) a solution comprising nucleation-center forming entities for binding to components of said target if said target is present in the sample (page 15, lines 9-19; page 20, lines 11-33; page 23, lines 6-15; page 25, lines 2-11)

; and (ii) a combination of metal ions and a reducing agent to allow formation of said conductive substance on said entities, and wherein the conductive substance, when deposited onto the complex, forms a conductive bridge between the at least two electrodes of a set (page 18, lines 22-31; page 25, lines 12-29); and

(d) means for determining whether the one or more targets are in the sample as a result of the extent of electric conductance between the at least two electrodes of each assay set (page 3, lines 1-11; page 7, lines 31-38; page 8, lines 1-14; page 9, lines 27-38; page 10; page 11, lines 1-4; page 24, 25; page 26, lines 1-27).

Regarding claim 24, Mroczkowski et al. teach step e) of the method namely determining conductance between said at least two electrodes, wherein conductance above a threshold conductance indicates the presence of a respective target in the sample while conductance below a threshold conductance indicates the absence of any targets in the sample (page 8 lines 27- page 9 lines 1-4 where measurement of conductance of control vs. actual test samples is taught and resistance values corresponding to specific antigen levels in the sample are taught thus teaching conductance of threshold values the negative control provides the lower threshold and resistance values of specific antigen levels are all above this threshold conductance).

Regarding claim 25, Mroczkowski et al. teach step a) reacting a sample which may or may not have targets with a first reagent solution to bind nucleation center-forming entities to said targets (see page 6 lines 1-13 where patient and control samples are taught, thus teaching reacting a sample which may or may not have targets with a first reagent solution to bind nucleation center-forming entities to said targets).

Regarding claim 26, Mroczkowski et al. teach steps c) and d) namely

Art Unit: 1637

(c) contacting said device with a first reagent solution comprising monomers of a conductive polymer such that said monomers can bind to complexes formed between the targets and recognition moieties (see page 14 lines 23-33 where gold particles or gold coated polystyrene spheres are taught as monomers);

(d) treating said device such that said monomers will polymerize to form a conducting polymer, such that upon polymerization of the monomers a conductive bridge between the at least two electrodes of at least one set is formed (see page 14 line 23 where layers of suitable conducting material such as gold etc is taught, by teaching conducting layer of gold, Mroczkowski et al. inherently teach polymerization of monomers to form a conducting polymer, see page 33 claim 5 steps 4 and 5; where coating aggregates with electrically conductive substance and measuring a change in current flow through said circuit caused by the presence of said aggregates in said channel is taught. Thus by teaching the flow of current through circuit Mroczkowski et al. teach formation of a conductive bridge between the at least two electrodes of at least one set is formed).

Thus all the elements recited in claims 1, and 24-26 are anticipated by Mroczkowski et al.

Regarding claims 4, and 6, Mroczkowski et al. teach wherein said nucleation-center forming entities are colloid particles (claim 4) and colloid gold particles (claim 6) (see page 9 line 35 where colloidal gold is taught).

Regarding claims 5, and 7, Mroczkowski et al. teach wherein said nucleation-center forming entities are metal complexes, clusters, or complexes and clusters-claim 5 and metal complexes or clusters are gold complexes or gold clusters. (see page 14 lines 29-33 where plastic particles having a conductive metal coating, especially gold-coated polystyrene spheres are taught)

Regarding claims 8 and 9, Mroczkowski et al. teach platinum (see page 14 line 28)

Regarding claim 18, Mroczkowski et al. teach a system comprising a plurality of assay sets of electrodes (see fig. 8 page 17 lines 4-17).

Regarding claim 19, Mroczkowski et al. teach wherein all assay sets of electrodes are for assaying the same component of the same target (see page 29 example 4 and Table 4 where all assay sets were designed to detect rabbit IgG).

Regarding claim 20, Mroczkowski et al. teach wherein different assay sets of electrodes or different groups of assay sets are for assaying different targets (see page 5 lines 6-9 where different targets are taught). (see fig. 8 and 9 where multiplexing is taught and measurement of conductance from each assay set is performed using ohmmeter).

Regarding claims 22 and 23, Mroczkowski et al. teach when the target is a protein or polypeptide and the recognition moiety is a protein-binding molecule which specifically binds to the target protein (see page 5 lines 21-35 where target antigen 12A is taught along with antibody 15A is taught as the recognition moiety

Art Unit: 1637

which is a protein-binding molecule which specifically binds to the target protein 12A).

Regarding claim 27, Mroczkowski et al. teach comprising before step (a) reacting the sample with a second reagent solution containing entities which can form nucleation centers for growing therefrom a conductive polymer from said monomers, such that said entities bind to said targets if present in the sample (see page 9 lines 33—36 where preincubation is omitted and directly sample 11A and colloidal gold 13A is reacted. Here colloidal gold 13A a second reagent solution containing entities which can form nucleation centers for growing therefrom a conductive polymer from said monomers, such that said entities bind to said targets if present in the sample).

Regarding claim 28, Mroczkowski et al. teach comprising after step (a) contacting said assay device with a second reagent solution containing entities which can form nucleation centers for growing therefrom a conductive polymer from said monomers, such that said entities bind to said targets if bound to said recognition moieties (see page 10 line 14 where second, conductively labeled antibody is taught as a second reagent solution containing entities which can form nucleation centers for growing therefrom a conductive polymer from said monomers, such that said entities bind to said targets if bound to said recognition moieties) .

Regarding claim 45, Mroczkowski et al. teach further comprising contacting said assay device with a first reagent solution to form nucleation-center forming entities for depositing onto or binding to complexes formed

Art Unit: 1637

between a target and a recognition moiety (see page 15, lines 9-19; page 20, lines 11-33; page 23, lines 6-15; page 25, lines 2-11).

Regarding claim 57, Mroczkowski et al. teach further comprising a sample which may or may not have the target (see page 8 lines 31-33 where patient sample 11A is taught it may or may not contain antigen 12A in the sample 11A thus teaching a sample which may or may not have the target) .

Claim Rejections - 35 USC § 103

15. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

16. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

17. Claims 29, 43-44, 47-51, 55-56 and 65 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mroczkowski et al. (WO 90/05300;

Art Unit: 1637

cited in the IDS) as applied to claims 1, 24, 25, 26, 35 and 37 above further in view of and Hollis et al. (U.S. Patent No. 5,653,939 A).

Regarding claim 29, Mroczkowski et al. teach the method of claim 24, but do not teach wherein said targets are nucleic acid molecules and the recognition moieties are oligonucleotides.

Regarding claim 29, Hollis et al. teach wherein said targets are nucleic acid molecules and the recognition moieties are oligonucleotides each of which has a sequence which is complementary to a nucleic acid molecule of said target (see col. 6 lines 35-52).

Regarding claim 43, Hollis et al. teach wherein said one or more targets are one or more nucleic acid sequences (see col. 6 lines 48-49).

Regarding claim 44, Hollis et al. teach wherein said recognition moiety is an oligonucleotide having a sequence complementary to at least a portion of sequence of one of said one or more targets (see col. 6 lines 42-52).

Regarding claims 47, 48 Hollis et al. teach wherein said targets are nucleic acid molecules and the recognition moieties are oligonucleotides, each of which has a sequence which is complementary to a nucleic acid molecule of said target (see claims 43 and 44 above).

Regarding claims 49, 50, 51 Hollis et al. teach wherein said targets are selected from the group consisting of a bacterium component, a virus component, and a cell component (see col. 1 lines 20-26).

Regarding claim 55 Hollis et al. teach wherein said means comprises a computer (see col. 7 line 4 where computer is taught).

Regarding claim 56 Hollis et al. teach wherein said means comprises a scanner for analyzing a plurality of assay sets (see col. 12 lines 10-12 where scanner is taught).

Regarding claim 65, Mroczkowski et al. teach a system for assaying one or more targets in a sample comprising:

(a) an assay device having one or more assay sets (see page 18 lines 1-8 where multiple assay sets are taught),

the assay sets comprising at least two electrodes (see Fig. 1 and 2. Elements 23 and 24 shown in figs a 23A and 24A in Fig. 1 and 23B and 24B in Fig. 2 are at least two electrodes. Also see page 6 lines 20- 21)

and a recognition moiety immobilized to each of the electrodes (see page 10 lines 7-13 where immobilized antibody=recognition moiety is taught),

each recognition moiety being an antibody capable of specific binding to an epitope of a target selected from the group consisting of a bacterium, a virus, and a cell (see page 5 line 6-10 where detection of antigens in the fluids or tissues of human or animals is taught. By teaching antigens Mroczkowski et al. teach an epitope of a target selected from the group consisting of a bacterium, a virus, and a cell which all have antigenic epitopes on their surfaces);

(b) an electric or electronic module arranged and configured to measure electric conductance between the at least two electrodes of each assay set (see page 8 lines 8-14);

(c) reagents formulated to deposit a conductive substance onto a complex formed between said recognition moiety and said target, wherein the reagents

Art Unit: 1637

comprise: (i) a solution comprising nucleation-center forming entities for binding to components of said target if said target is present in the sample (page 15, lines 9-19; page 20, lines 11-33; page 23, lines 6-15; page 25, lines 2-11)

; and (ii) a combination of metal ions and a reducing agent to allow formation of said conductive substance on said entities, and wherein the conductive substance, when deposited onto the complex, forms a conductive bridge between the at least two electrodes of a set (page 18, lines 22-31; page 25, lines 12-29); and

Regarding step d) Mroczkowski et al. teach microelectronics for determining whether the one or more targets are in the sample as a result of the extent of electric conductance between the at least two electrodes of each assay set (See page 3, lines 1-11; page 7, lines 31-38; page 8, lines 1-14; page 9, lines 27-38; page 10; page 11, lines 1-4; page 24, 25; page 26, lines 1-27).

Regarding step d) Mroczkowski et al. do not teach a computer as recited in the presently amended claim.

Regarding step d) Hollis et al. teach a computer that is used for collecting and processing data (see col. 8 lines 61-65 where detection by means of a monolithically integrated charge-coupled device (CCD) is taught to detect presence or absence of hybridized molecules. By teaching a monolithically integrated charge-coupled device (CCD) Hollis et al. teach a computer).

Hollis et al. also teach detection of an epitope of a target selected from the group consisting of a bacterium, a virus, and a cell (see col. 18 lines 47-52).

It would have been prime facie obvious to one of ordinary skill in the art to combine the computer taught by Hollis et al. in the microelectronic system taught by Mroczkowski et al. at the time the invention was made. The motivation to do so is provided by Hollis et al. who state "The present invention can be used in connection with detection of targets which are molecular structures other than DNA or RNA, such as cells and antibodies.-----The technology described here employs those well understood binding interactions in a new microelectronic detection scheme. The commercial application of the methodology is for use to detect the presence of any of hundreds of thousands of different antibodies or other proteins, simultaneously, in a blood sample or other biological fluid. This is particularly useful in blood typing, the detection of viral infection such as AIDS, or the diagnosis of cancer." (see col. 18 lines 3-53). Thus one of ordinary skill can immediately see the advantages of using a computer to process the huge amount of data that will be generated using these micro fabricated device resulting in more accurate, cheaper, faster and more efficient processing of multiple clinical samples as compared to manually recording the conductivity measurements obtained from the microelectronic circuits taught by Mroczkowski et al.

18. Claims 35, 37, 38, 39 and 41 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mroczkowski et al. (WO 90/05300; cited in the IDS) as applied to claims 18, 24 in view of Olsen (US pat. 5,614,832 issued March 25, 1997).

Art Unit: 1637

Regarding claims 35, Mroczkowski et al. teach an electronic device for determining the presence or absence of one or more targets in a sample comprising:

an integrated circuit (see Fig. 8) comprising a first group of N1 conductors (see fig. 7 element 51 is first group of N1 conductors)

and a second group of N2 conductors (see fig. 7 element 52 is second group of N2 conductors), defining between them $N1 \times N2$ junctions (fig. 7 element 53), each such junction being formed with an electronic module comprising two electrodes (fig. 8 layer 23 and 24 are electrodes), each electrode linked to or defined as an integral portion of one of the conductors (element 61 and 62 in Fig. 8 are conductors) and supported by a common substrate (base 22 in Fig. 8 is common substrate),

whereby a current flowing between one conductor of the first group to one conductor of the second group of conductors defines a single junction point between them (see page 18 lines 9-21 where Fig. 9 is described); each pair of electrodes forming part of an assay set (see fig. 8 where 23/24 each pair is shown to form an assay set),

each assay set having a recognition moiety for binding to a component of a target (see page 5 line 29 where antibodies= recognition moiety are taught) selected from the group consisting of a bacterium, a virus, and a cell (see page 5 line 6-10 where detection of antigens in the fluids or tissues of human or animals is taught. By teaching antigens Mroczkowski et al. teach a bacterium, a virus, and a cell which all have antigens on their surfaces), the recognition moiety

Art Unit: 1637

bound to the substrate and positioned between the electrodes (see page 18 lines 3-8 where each assay set composed of pair of layers 23 and 24 is taught to have a different recognition moiety or no recognition moiety—for negative control or same recognition moiety bound to the substrate and positioned between the electrodes is taught) ;

the assay sets adapted to accept reagents formulated to deposit a conductive substance onto a complex formed between said recognition moiety and said target, wherein said reagents comprise:

(i) a solution comprising nucleation-center forming entities for binding to components of said target if said target is present in the sample (page 15, lines 9-19; page 20, lines 11-33; page 23, lines 6-15; page 25, lines 2-11)

; and (ii) a combination of metal ions and a reducing agent to allow formation of said conductive substance on said entities, (page 18, lines 22-31; page 25, lines 12-29); and

means for determining whether the one or more targets are in the sample as a result of the extent of electric conductance between the two electrodes of each assay set (see page 25 line 28-29 where ohmmeter is taught as a means for determining whether the one or more targets are in the sample as a result of the extent of electric conductance between the two electrodes of each assay set).

Regarding claim 37, Mroczkowski et al. teach an electric device for determining the presence or absence of one or more targets in a sample comprising:

a microelectronic device having a plurality of layers, with a first group of conductors being defined as stripes in one or more first layers and a second group of conductors being defined as stripes in one or more second layers of the device with each of said second layers being separated from a first layer by a non-conductive substance, electrodes of the device being formed as open ends of the conductors by openings or cut-outs in a vertical direction through the layers (see section D photolithography on page 21 lines 21-page 22 lines 1-27 where formation of microelectronic device with above features is described);

each pair of electrodes forming part of an assay set, each assay set having a recognition moiety for binding to a component of a target selected from the group consisting of a bacterium, a virus, and a cell (see page 5 line 6-10 where detection of antigens in the fluids or tissues of human or animals is taught. By teaching antigens Mroczkowski et al. teach a bacterium, a virus, and a cell which all have antigens on their surfaces) bound to one or more layer in the vertical opening or cut-out (this is the gap described in claim 1); wherein the assay sets are adapted to accept reagents formulated to deposit a conductive substance onto a complex formed between said recognition moiety and said target, wherein said reagents comprise:

(i) a solution comprising nucleation-center forming entities for binding to components of said target if said target is present in the sample (page 15, lines 9-19; page 20, lines 11-33; page23, lines 6-15; page 25, lines 2-11); and

Art Unit: 1637

(ii) a combination of metal ions and a reducing agent to allow formation of said conductive substance on said entities (page 18, lines 22-31; page 25, lines 12-29), and

means for determining whether the one or more targets are in the sample as a result of the extent of electric conductance between the pair of electrodes of each assay set (see page 25 line 28-29 where ohmmeter is taught as a means for determining whether the one or more targets are in the sample as a result of the extent of electric conductance between the two electrodes of each assay set).

Regarding claims 38, Mroczkowski et al. teach wherein the device is an electronic device for determining one or more targets in a sample, comprising:

an integrated circuit (see Fig. 8) comprising a first group of N1 conductors (see fig. 7 element 51 is first group of N1 conductors)

and a second group of N2 conductors (see fig. 7 element 52 is second group of N2 conductors), defining between them $N1 \times N2$ junctions (fig. 7 element 53), each such junction being formed with an electronic module comprising two electrodes (fig. 8 layer 23 and 24 are electrodes), each electrode linked to or defined as an integral portion of one of the conductors (element 61 and 62 in Fig. 8 are conductors) and

each pair of electrodes forming part of an array set (see fig. 8 and 9 where array sets are shown), each array set having a recognition moiety bound to at least one of the electrodes (see page 24 example 2 where binding of IgG recognition moiety is taught to diagnostic elements= electrodes).

Regarding claims 35, 38 and 39 Mroczkowski et al. do not teach wherein the circuit further comprises a diode or non-linear component permitting current flow through the electronic module only in the direction from the first group of conductors to the second group of conductors.

Regarding claim 38, Mroczkowski et al. also do not teach

2) whereby a current flowing between one conductor of the first group to the one conductor of the second group of conductors defines a single junction point between them;

Regarding claims 35, 38 and 39 Olsen teaches wherein the circuit further comprises a diode or non-linear component permitting current flow through the electronic module only in the direction from the first group of conductors to the second group of conductors (see abstract).

Regarding claim 38, by teaching diode Olsen inherently teaches whereby a current flowing between one conductor of the first group to the one conductor of the second group of conductors defines a single junction point between them (this is because most modern diodes are based on semiconductor p-n junctions. In a p-n diode, conventional current can flow from the p-type side (the anode) to the n-type side (cathode), but cannot flow in the opposite direction, thus a current flowing between one conductor of the first group to the one conductor of the second group of conductors defines a single junction point between them);

Regarding claim 41, Mroczkowski et al. teach wherein different assay sets of electrodes or different groups of assay sets are for assaying different targets (see page 5 lines 6-9 where different targets are taught). (see fig. 8 and 9 where

Art Unit: 1637

multiplexing is taught and measurement of conductance from each assay set is performed using ohmmeter).

It would have been *prima facie* obvious to one of ordinary skill in the art to incorporate the in circuit ohmmeters containing diode taught by Olsen into the system taught by Mroczkowski et al. at the time the invention was made. The motivation to do so is provided to one of ordinary skill in the art by both Olsen as well as the art itself.

Art teaches one of ordinary skill that diode is a two-terminal device that have two active electrodes between which the signal of interest may flow, and most are used for their unidirectional electric current property. According to Wikipedia the most common function of a diode is to allow an electric current to pass in one direction and to block it in the opposite direction (reference downloaded on August 13, 2008 provided). Thus, the diode can be thought of as an electronic version of a check valve. In view of this knowledge and teaching by Olsen that a circuit that has a plurality of diodes connected across the input terminals serve as a current generator protection circuit (see abstract), one of ordinary skill in the art can immediately see the advantage of using the diodes in the system taught by Mroczkowski et al. By using the diodes the integrated circuits present in the microelectronic device would be electrically isolated from each other so measurement of electrical conductance at each junction would be independent and unaffected by the measurement at any other junction.

19. Claims 36, 53-54 and 60-63 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mroczkowski et al. (WO 90/05300; cited in the IDS) and Olsen

(US pat. 5,614,832 issued March 25, 1997) as applied to claims 35 and 37 above further in view of Hollis et al. (U.S. Patent No. 5,653,939 A).

Regarding claim 36, Mroczkowski et al. and Olsen teach the device of claim 35, but do not teach wherein distance of center of one assay set to a center of an adjacent assay set is 100 μm or less.

Regarding claim 36, Hollis et al. teach wherein distance of center of one assay set to a center of an adjacent assay set is 100 μm or less (see col. 6 line 15-18 where a spacing of 2 microns is taught between the array of 2 micron wide wells. Thus teaching wherein distance of center of one assay set to a center of an adjacent assay set is 100 μm or less).

Regarding claim 53, Mroczkowski et al. and Olsen teach the device of claim 35, but do not teach wherein said recognition moiety is a nucleic acid molecule.

Regarding claims 53, 54 Hollis et al. teach wherein said recognition moiety is a nucleic acid molecule (see col. 6 lines 42-52).

Regarding claims 60, 62 Hollis et al. teach wherein said means comprises a computer (see col. 7 line 4 where computer is taught).

Regarding claim 61, 63 Hollis et al. teach wherein said means comprises a scanner for analyzing a plurality of assay sets (see col. 12 lines 10-12 where scanner is taught).

It would have been *prime facie* obvious to one of ordinary skill in the art to combine the computer taught by Hollis et al. in the microelectronic system taught by Mroczkowski et al. and Olsen at the time the invention was made. The

Art Unit: 1637

motivation to do so is provided by Hollis et al. who state "The present invention can be used in connection with detection of targets which are molecular structures other than DNA or RNA, such as cells and antibodies.-----The technology described here employs those well understood binding interactions in a new microelectronic detection scheme. The commercial application of the methodology is for use to detect the presence of any of hundreds of thousands of different antibodies or other proteins, simultaneously, in a blood sample or other biological fluid. This is particularly useful in blood typing, the detection of viral infection such as AIDS, or the diagnosis of cancer." (see col. 18 lines 3-53). Thus one of ordinary skill can immediately see the advantages of using a computer to process the huge amount of data that will be generated using these micro fabricated device resulting in more accurate, cheaper, faster and more efficient processing of multiple clinical samples as compared to manually recording the conductivity measurements obtained from the microelectronic circuits taught by Mroczkowski et al. and Olsen.

Conclusion

20. All claims under consideration 1, 4-9, 18-20, 22-29, 35-45, 47-51, 53-57, 60-63 and 65 are rejected over prior art. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUCHIRA PANDE whose telephone number is (571)272-9052. The examiner can normally be reached on 8:30 am -5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax

Art Unit: 1637

phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Suchira Pande
Examiner
Art Unit 1637

/Teresa E Strzelecka/
Primary Examiner, Art Unit 1637
August 14, 2008